Article
Bharat Biotech's Covaxin shows 77.8% efficacy in Phase 3 trial
Rating:
0.0
Views:
70
Likes:
1
Library:
1
Bharat Biotech on Saturday announced the efficacy analysis data from Phase 3 clinical trials of its Covid vaccine Covaxin. The vaccine has been found to be 77.8 per cent effective.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value